Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 5, Pages 317–325
Research Article

Serum Anti-CCNY Autoantibody Is an Independent Prognosis Indicator for Postoperative Patients with Early-Stage Nonsmall-Cell Lung Carcinoma

Department of Cellular & Molecular Biology, Beijing TB and Thoracic Tumor Research Institution/Beijing Chest Hospital, Capital Medical University, 97 Beimachang, Tongzhou, Beijing 101149, China

Received 15 June 2013; Revised 20 August 2013; Accepted 21 August 2013

Academic Editor: Sun-Il Hwang

Copyright © 2013 Li Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cyclin Y (CCNY) is a novel cyclin and almost nothing is known about its role in human cancers. To investigate the clinical significance of serum anti-CCNY autoantibodies in nonsmall-cell lung carcinoma (NSCLC), the serum levels of CCNY protein in 264 patients with NSCLC, 103 patients with tuberculosis, and 89 healthy controls were analyzed by immunohistochemistry. The result shows that, compared with normal lung tissues, the NSCLC tissues contained higher levels of CCNY protein. The levels of anti-CCNY autoantibodies were higher in the sera of the patients with NSCLC than in the sera of the healthy controls ( ) or the patients with tuberculosis ( ). Moreover, in a Cox regression analysis, anti-CCNY autoantibody was an independent factor that predicted poor prognosis for postoperative patients with early-stage NSCLC ( ) as well as for those with distant metastasis ( ). Our data indicated that Anti-CCNY autoantibody may be useful as a latent tumor marker to facilitate diagnosis and may represent a novel prognostic indicator for patients with early stage NSCLC.